PPM1H is a p27 phosphatase implicated in trastuzumab resistance

Si Tuen Lee-Hoeflich1,4, Thinh Q. Pham1, Don Dowbenko1, Xander Munroe1, James Lee1, Li Li1, Wei Zhou1, Peter M. Haverty1, Kanan Pujara1, Jeremy Stinson1, Sara M. Chan1, Jeffrey Eastham-Anderson1, Ajay Pandita1, Somasekar Seshagiri1, Klaus P. Hoeflich1, Gulisa Turashvili2, Karen A. Gelmon3, Samuel A. Aparicio2, David P. Davis1, Mark X. Sliwkowski1 & Howard M. Stern1

1 Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA 94080, USA.

2 Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver V5Z 1L3, Canada.

3 Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver BC, V5Z 1L3, Canada.

4 Present address: Novartis Institute for Biomedical Research, 4560 Horton Street, Emeryville, CA 94608, USA

Running Title: Role of PPM1H in p27 regulation

Key Words: HER2, Trastuzumab, p27, PPM1H, Resistance

Abbreviations: HER, Human Epidermal growth factor Receptor; CDK, Cyclin Dependent Kinase; siRNA, Short Interfering RNA; shRNA, Short Hairpin RNA

Corresponding author: Howard M. Stern
 Genentech, Inc.
 1 DNA Way
 South San Francisco, CA 94080
 email hstern@gene.com

Conflict of Interest Statement: TP, DD, XM, JL, LL, WZ, PMH, JS, SC, JEA, SS, KPH, MXS, and HMS are employees of Genentech Research and Early Development and are shareholders in Roche Holding, AG.
Abstract

The HER2 oncogene is overexpressed or amplified in 20% of breast cancers. HER2-positive cancer historically portends a poor prognosis, but the HER2-targeted therapy trastuzumab mitigates this otherwise ominous distinction. Nevertheless, some patients suffer disease recurrence despite trastuzumab, and metastatic disease remains largely incurable due to innate and acquired resistance. Thus, understanding trastuzumab resistance remains an unmet medical need. Through RNAi screening, we discovered that knockdown of the serine/threonine phosphatase PPM1H confers trastuzumab resistance via reduction in protein levels of the tumour suppressor p27. PPM1H dephosphorylates p27 at threonine 187, thus removing a signal for proteasomal degradation. We further determined that patients whose tumours express low levels of PPM1H trend towards worse clinical outcome on trastuzumab. Identifying PPM1H as a novel p27 phosphatase reveals new insight into how cancer cells destabilize a well-recognized tumour suppressor. Furthermore, low PPM1H expression may identify a subset of HER2-positive tumors that are harder to treat.

Significance

PPM1H is identified as a phosphatase impacting p27 stability. Low expression of PPM1H may be associated with poor outcome in breast cancer.
Introduction

Trastuzumab (Herceptin®) is an anti-human epidermal growth factor receptor 2 (HER2, ERBB2) therapeutic monoclonal antibody that provides significant clinical benefit for breast cancer patients whose tumors exhibit overexpression or amplification of the oncogene HER2 (1). Trastuzumab acts, at least in part, by blocking the interaction between overexpressed HER2 and its dimerization partner HER3, resulting in inhibition of oncogenic PI3K pathway signaling and subsequent upregulation of the cyclin dependent kinase (CDK) inhibitor p27 (2-7). PI3K pathway inhibition also causes translocation of p27 from the cytoplasm to the nucleus, where it is able to inhibit CDK/cyclin complexes (8-10).

Due to the molecular heterogeneity of cancer, not all patients with HER2-amplified tumors respond to HER2-targeted agents. In the metastatic setting, those that derive initial benefit often exhibit evolution of the tumor with resultant progression on therapy. One major hypothesis on the mechanism of resistance to HER2-targeted therapy is that the PI3K pathway may be independently activated downstream of the HER2-HER3 receptor complex via loss of PTEN or acquisition of activating PIK3CA mutations (2, 11, 12). A recent preclinical study demonstrates that trastuzumab-resistant models harboring PTEN loss or PIK3CA activating mutations are sensitive to GDC-0941, a class 1A PI3K small molecule inhibitor (2). This finding illustrates how understanding the molecular nature of resistance can reveal potentially more effective diagnostic/therapeutic co-development strategies to better treat individual patients.

While PTEN loss and PIK3CA activating mutations may play a role in trastuzumab resistance, we hypothesized that there could be additional resistance factors for several reasons. First, the PI3K signalling pathway is known to elicit a complex network of downstream events which may involve regulatory factors other than PTEN and PIK3CA (13). Second, there is ample evidence that the HER2/3 complex may
activate signalling pathways other than PI3K, such as the MAPK pathway (14). Third, the downstream effect of trastuzumab primarily involves inhibition of the G1/S transition via stabilization of the cell cycle inhibitor p27 (4-7), raising the possibility that downstream cell cycle regulators may also impact response to trastuzumab.
Results

siRNA screen for trastuzumab resistance genes

To determine if there are additional downstream trastuzumab resistance factors other than PTEN and PIK3CA, we conducted a functional screen to identify genes that, upon silencing, augment proliferation of trastuzumab-treated BT474 (HER2-amplified) breast cancer cells (Fig. 1A). Small interfering RNA (siRNA) knockdown of either p27 or PTEN increased proliferation in the presence of trastuzumab, consistent with the literature (11, 12, 15-17) (Fig. 1B). Notably, knockdown of p27 was more potent at abrogating trastuzumab response than was knockdown of PTEN. Both PTEN and p27 siRNAs were used as positive controls as we screened siRNA libraries of human kinases (795 genes) and phosphatases (159 genes). Each gene was targeted separately by four individual siRNA oligonucleotides, and the relative cell growth was assessed via $^3$H-thymidine incorporation. Knockdown of 31 genes yielded significantly increased proliferation (Z-score >1.5) with at least 2 of the 4 independent siRNA oligonucleotides and were validated in a repeat assay (Table 1). Included in the libraries were siRNA oligonucleotides targeting PTEN and p27 (CDKN1B), and both of these positive controls were identified as hits (Fig. 1C), further validating the method of screening.

The initial screen hits were further prioritized by testing reproducibility in other HER2-overexpressing cell lines (BT474M1, SKBR-3), by assessing potency of phenotype, and by testing robustness of gene knockdown by qRT-PCR. Aside from PTEN and p27, 3 kinases (DYRK1A, STK10, and STYK1) and 2 phosphatases (PPM1H and PTPN11) were identified based on these criteria as being the top hits (Fig. 2A, Supplementary Fig. S1). Gene knockdown increased cell proliferation not only in the presence of trastuzumab, but also in the absence of trastuzumab. Thus, the evidence suggests that while these genes may have a role in trastuzumab resistance, they are not
specific to HER2 and may have broader significance in cancer cell cycle regulation, much like PTEN and p27.

**PPM1H loss causes trastuzumab resistance**

Of the 5 top hits, knockdown of PPM1H stood out as being the most potent at augmenting proliferation in the presence of trastuzumab (Fig. 2A), thus we focused on better understanding the role of PPM1H in cell proliferation and trastuzumab resistance. PPM1H is a member of the PP2C family of ser/thr phosphatases distinguished by the dependence on Mn$^{2+}$ or Mg$^{2+}$ for catalytic activity (18). Although PPM1H was recently implicated as an oncogene in colon cancer (19, 20), it was originally identified as a negative regulator of neurite outgrowth (21). In fact, many PP2C family members have been described as negative regulators of growth having substrates in the PI3K pathway, the JNK pathway, or in cell cycle regulation (e.g. cyclin dependent kinases) (18). Very little is known about the mechanism of PPM1H and how it might impact proliferation.

The same phenotype was observed with 3 of 4 independent siRNA oligonucleotides targeting PPM1H, (Supplementary Fig. S1), suggesting that the proliferative effect is not likely due to off-target activity. Nevertheless, to further rule out any possibility of off target effects, PPM1H shRNA was transfected into BT474 cells along with a control vector or a PPM1H expression vector carrying synonymous mutations within the shRNA targeted region, thus rendering the exogenous transcript resistant to knockdown. The PPM1H shRNA caused trastuzumab resistance, similar to the result with siRNA (Fig. 2B). However, when PPM1H shRNA was co-expressed with PPM1H carrying synonymous mutations, trastuzumab sensitivity was restored (Fig. 2B), providing further evidence that the observation with PPM1H is not likely due to off-target effects.
Many studies have suggested that 3D culture may more closely mimic the milieu of a tumour mass (22). To determine the impact of PPM1H knockdown in 3D culture, we created stable BT474M1 cell lines carrying doxycycline (dox)-inducible PPM1H shRNA. Treatment of the cell line with dox in 2D culture resulted in PPM1H knockdown at the mRNA and protein level and resulted in trastuzumab resistance, much like PPM1H siRNA. The same cell line was grown in 3D culture for 10 days in the presence or absence of dox, after which colony size was visualized and quantified. In the absence of dox, trastuzumab treatment resulted in significantly smaller colony size compared to untreated colonies; in the presence of dox, the trastuzumab effect was significantly diminished (Fig. 2C and Supplementary Fig. S1). PPM1H knockdown was verified at the protein level in the 3D culture model, and dox treatment of a negative control inducible LacZ shRNA cell line did not impact the trastuzumab effect (Supplementary Fig. S1). Thus, the phenotype observed in 3D culture supports the conclusion that PPM1H knockdown augments cell growth and causes trastuzumab resistance.

**PPM1H is a p27 T187 phosphatase**

To elucidate the molecular mechanism of PPM1H in cell proliferation, we examined the effect of PPM1H knockdown on the PI3K-Akt pathway, a key oncogenic signalling axis in HER2-amplified cells (23, 24). We speculated that the phosphatase activity of PPM1H might inactivate this pathway since PHLPP, a PPM1H-related family member, has previously been shown to dephosphorylate AKT (25). However, knockdown of PPM1H did not change the phosphorylation levels of AKT, HER2 or HER3. Furthermore, there was no evidence for modulation of the MAPK pathway as assessed by pERK (Supplementary Fig. S2).

We next examined the CDK inhibitor p27 and found significant modulation with PPM1H knockdown compared to both untreated and trastuzumab-treated control cells.
p27 protein levels as assessed by Western blot and immunofluorescence dropped with PPM1H knockdown (Fig. 3A, B), and this was supported by quantitative image analysis of the immunofluorescence (Supplementary Fig. S2), consistent with the observed increase in cell proliferation. No change in p27 mRNA levels was observed with PPM1H knockdown, suggesting that loss of p27 is due to an alteration in protein stabilization.

p27 is known to undergo ubiquitin-mediated proteasomal degradation which is initiated by phosphorylation of p27 at T187 by CDK2 in complex with cyclin A or E (26, 27). T187 phospho-p27 is recognized by the F-box protein SKP2 which brings p27 to the COP9 signalosome (CSN) for ubiquitylation (28). Recently SKP2 was shown to be phosphorylated and stabilized by AKT1 at S72 (29, 30). However, p27 also plays a role in regulating SKP2 via inhibition of CDK2 resulting in dephosphorylation and destabilization of SKP2 (31). Given this reciprocal regulation of p27 and SKP2, we hypothesized that PPM1H knockdown might be associated with increased SKP2 protein. This hypothesis was tested via Western blot and immunofluorescence, and the results clearly indicate that SKP2 protein increases while p27 decreases in the setting of PPM1H knockdown (Fig. 3 A, C and Supplementary Fig. S2). No change in SKP2 mRNA was observed, consistent with the conclusion that PPM1H knockdown promotes SKP2 protein stability.

Because PPM1H belongs to a ser/thr phosphatase family, it is possible that PPM1H might directly dephosphorylate p27 or SKP2. To explore these hypotheses, we first examined the subcellular localization of PPM1H. Nuclear/cytoplasmic fractionation revealed that PPM1H is present in both the nucleus and the cytoplasm (Supplementary Fig. S3A). Enzymatically active recombinant flag-PPM1H was then screened for activity on in vitro synthesized phospho-peptides representing the major known phosphorylation sites on p27 (S10, T157, T187) and SKP2 (S72, S75, S64).
Liberation of phosphate was observed with the p27 peptides, most notably with the T187 peptide (Fig. 4A). No evidence for PPM1H mediated dephosphorylation of the SKP2 phospho-peptides was observed.

To further examine a potential role for PPM1H in dephosphorylating p27, HA-tagged p27 bound to anti-HA conjugated agarose beads was incubated in vitro with CDK2/cyclin A to phosphorylate T187. After washing 3 times to remove the CDK2/cyclin A, the phosphorylated p27 was subsequently incubated with flag-PPM1H or flag-PPM1H-H153L in ATP-free buffer. The H153L mutant was predicted to disrupt enzyme activity based on a prior mutational analysis of murine PPM1B (32). Indeed the PPM1H-H153L mutant was found to have decreased enzymatic activity in a synthetic phosphatase assay (Supplementary Fig. S3B). Wildtype PPM1H but not PPM1H-H153L dephosphorylated p27 at T187 (Fig. 4B). The pre-phosphatase (lower gel) and post-phosphatase (upper gel) phospho-T187 bands were quantified by densitometry which suggested that PPM1H diminished phosphorylation by about half. Although there appears to be more phospho-T187 in the PPM1H-H153L treated lane (upper gel), the pre-phosphatase control reveals that this sample had more phospho-T187 before the addition of phosphatase, and the quantified ratio is 1.1, indicating little to no change with PPM1H-H153L treatment. While the S10 site on p27 was not phosphorylated by CDK2/cyclin A, there was some endogenous phosphorylation observed. PPM1H exhibited no activity at the S10 site in this assay, suggesting specificity for T187.

Specificity of PPM1H was further explored via GST-tagged versions of PPM1H and the most closely related family member PPM1J. GST-PPM1H and GST-PPM1J exhibited similar enzymatic activity in a synthetic phosphatase assay (Supplementary Fig. S3C) but only PPM1H was effective at dephosphorylating p27 at T187 (Fig. 4C).
Neither enzyme exhibited activity at S10. Together these data further support the hypothesis that PPM1H is a specific p27-T187 phosphatase.

Although PPM1H did not exhibit activity on SKP2 phosphopeptides, we nevertheless tested flag-PPM1H on full length SKP2. SKP2 was phosphorylated in vitro by AKT in the presence of $\gamma^{32}$P-ATP and was then incubated with phosphatase. $\lambda$-phosphatase was able to dephosphorylate SKP2 but PPM1H lacked activity (Supplementary Fig. S3D). These data further support the conclusion that unlike p27, SKP2 is not a substrate for PPM1H.

**Tumors with low PPM1H expression trend toward worse clinical outcome**

To explore whether expression of *PPM1H* might impact clinical outcome on trastuzumab, we developed an isotopic in situ hybridization probe to assay *PPM1H* mRNA in FFPE human breast cancer samples. *PPM1H* was examined in 87 HER2-positive tumor samples from patients who had been treated with trastuzumab. The sample set consisted of a mixture of first-line, second-line, and later-line patients from British Columbia, most of whom were treated with trastuzumab in combination with chemotherapy between 1998 and 2005 as previously described (33). Of 150 patient samples identified in the original study, 87 had sufficient tumor tissue with evidence of control $\beta$-actin signal and verified HER2 amplification by FISH. Areas enriched in invasive neoplastic cells were marked by a pathologist and a quantitative phosphor-imager analysis of *PPM1H* expression was performed in these regions. The samples were ranked based on *PPM1H* expression and the clinical outcome of the upper 50th percentile was compared to that of the lower 50th percentile. There was a trend toward poor outcome with low *PPM1H* expression (hazard ratio 1.6), although the data did not quite reach statistical significance ($p = 0.07, 95\% CI 0.96-2.6$) (Fig. 5A). The data were also examined for differences in clinical outcome based on *PPM1H* expression in the
ER-negative and ER-positive populations. The trend toward worse outcome with low PPM1H expression appeared largely restricted to the ER-negative population (Supplementary Fig. S4). These data suggest that low PPM1H expression could be a poor prognostic indicator in HER2-positive patients treated with trastuzumab. Further work in larger clinical datasets would be warranted to explore the significance of this trend.

To determine if the observation with PPM1H was independent from known PI3K pathway prognostic markers, we examined PTEN expression and PIK3CA mutation status in the same trastuzumab-treated samples. Low PPM1H expression was independent of PIK3CA mutation and PTEN expression status. Interestingly, in this sample set, neither decreased PTEN expression nor PIK3CA hotspot mutations were associated with poor outcome either alone or in combination (Supplementary Fig. S4).

In all cases in this sample set, PPM1H expression was observed to be low in normal breast epithelium and stroma, but appeared to be elevated in the epithelium of a proportion of the invasive breast cancers. In one case, PPM1H was observed to be elevated in pre-malignant glands (ductal carcinoma in situ), but was low in adjacent invasive cancer (Supplementary Fig. S4E). This observation raises the possibility that PPM1H is upregulated earlier in the oncogenic process and in some cases is later downregulated. To further explore this possibility, we examined PPM1H expression in a database of 159 frozen breast tissue samples that had undergone gene expression profiling at Gene Logic (now Osimum Biosolutions). No clinical outcome data was available for this sample set. Although ductal carcinoma in situ was not included in this sample set, there was evidence for elevated PPM1H expression in some primary tumours compared to normal and benign fibrocytic breast tissue. However, metastatic tumour tissue exhibited decreased PPM1H expression compared to primary tumours (Supplementary Fig. S4F). Taken together, the data are consistent with a pattern of
PPM1H expression tending to be increased in early stages of disease and decreased at later stages.

PPM1H mRNA was also examined in a set of cell lines and cancer tissues representing the major breast cancer subtypes. The basal-like subtype tends to lack expression of ER, PR and HER2 and is associated with poor prognosis (34). The luminal subtype expresses ER and PR, lacks HER2 amplification, and is associated with a better prognosis (34). About 50% of HER2-positive cancers are ER-positive, and there are reports that ER status is reflected in expression profiles resulting in HER2-basal and HER2-luminal groups, with HER2-basal exhibiting a worse prognosis (17, 35). Interestingly, breast cancer cell lines classified as basal or HER2-basal exhibited lower levels of PPM1H than did the luminal counterparts (Fig. 5B). A similar observation was made in breast cancer tissues (Fig. 5C). To determine whether HER2 pathway signalling might regulate PPM1H transcription, HER2 and HER3 were knocked down in BT474M1 cells, and PPM1H message was measured via qRT-PCR. There was no evidence for PPM1H transcriptional regulation by HER2 or HER3 (Supplementary Fig. S4).

PPM1H mRNA was also examined in a broad database of normal and tumor gene expression (Gene Logic). We observed that PPM1H expression is significantly decreased in glioblastoma and in renal cell carcinoma compared to normal brain and kidney, respectively (Supplementary Fig. S4). Interestingly, PPM1H is significantly increased in colon adenocarcinoma and prostate adenocarcinoma compared to normal colon and prostate, respectively (Supplementary Fig. S4). Thus, the role of PPM1H may depend upon the cancer type or even subtype.
Discussion

Diagnostic markers of poor outcome on therapy can be grouped into those that are prognostic (i.e. identify a particularly aggressive biology that is hard to treat) and those that are predictive of response to a specific therapy. Both types of diagnostic markers exhibit clinical utility and both can signify important disease biology. In the case of trastuzumab and lapatinib, prior bar code shRNA screens explored potential predictive markers of resistance by selecting for hits that impact long term cell growth in the setting of trastuzumab treatment, but not in the absence of treatment (11, 15). With this approach, the tumour suppressor PTEN was identified as the only hit. In the present study, we took a broader approach, seeking to identify any gene that increased proliferation in the setting of trastuzumab treatment, even if it also did so without treatment. We also utilized a different platform, choosing to use siRNA and directly measure proliferation rather than relying on long-term cell growth assays. With this different approach, we identified several novel hits which we speculate may represent genes of broader prognostic significance.

The top novel trastuzumab resistance factor identified in the screen and after extensive validation was the PP2C family member PPM1H. The PP2C family consists of metal dependent ser/thr phosphatases of which there are 16 in humans (18). The family is conserved throughout evolution with 7 PP2C family members existing in yeast (PTC1-7) (36). One important difference from other ser/thr phosphatase family members is that the PP2C family acts as monomers as opposed to requiring several subunits to achieve specifically targeted enzyme activity. The better characterized family members in humans include PPM1A and PPM1B which are negative regulators of growth and have been shown to dephosphorylate CDK2 as well as inhibit signalling through cellular stress pathways (18). The yeast PP2C family members (PTC2 and 3) are also described as negative regulators of growth by dephosphorylating and
inactivating Cdc28, a primary regulator of cell cycle progression (18). Other family members such as PTC1 are negative regulators of osmotic stress signalling pathways (36). Very little is known about PPM1H, although it was originally identified as a negative regulator of neurite outgrowth (21).

We explored whether PPM1H knockdown might impact total levels or phosphorylation of HER family members, immediate downstream PI3K or MAPK signalling components, or farther downstream cell cycle regulatory components. The only alteration that was consistently observed was a loss of nuclear p27, a key cell cycle regulator. This observation raised the hypothesis that PPM1H could be a phosphatase for p27, which we confirmed in vitro. Based on the existing data, we propose a model in which PPM1H dephosphorylates the T187 site on p27, thus preventing ubiquitylation and degradation (Fig. 6). Stabilized p27 would then be available to inhibit the cell cycle. Knockdown of PPM1H causes loss of nuclear p27 without evidence of cytoplasmic re-localization, consistent with the model that there is increased phosphorylation of p27 at T187 and subsequent proteasomal degradation of p27 in the nucleus. If PPM1H acted on the S10 and/or T157 phosphorylation sites on p27, one would have predicted to see evidence of cytoplasmic translocation and retention of p27.

This work is the first that we are aware of linking PPM1H to regulation of p27. This link raises interesting questions about what role PPM1H might play in regulating the cell cycle not only in HER2-positive breast cancer as described here, but also in other cancer types and in normal cell cycle regulation. It should be noted that while the observation that PPM1H can dephosphorylate p27 at T187 is intriguing, it is nevertheless possible that PPM1H might also act as a phosphatase for other proteins still to be determined. Furthermore, the antibody developed to detect PPM1H identifies two bands, both of which disappear with knockdown. This observation suggests that there
are 2 different forms of PPM1H. How these two forms differ molecularly and whether there are differences in substrate specificity or enzymatic activity is not known.

Consistent with the hypothesis that low PPM1H is associated with elevated proliferation, we found that there was a trend towards worse outcome in trastuzumab-treated patients whose tumours were HER2-amplified and had low PPM1H expression at the mRNA level. Based on the mechanism of PPM1H, this trend is consistent with many studies in the literature that have established low p27 expression and high SKP2 expression as poor prognostic indicators in breast cancer (26, 37-44). Furthermore, the cell cycle inhibitory activity of p27 on cyclin E/CDK2 complexes can be abrogated by cyclin D/CDK4 which binds p27 and titrates it away from cyclinE/CKD2. Interestingly, inactivation of both cyclin D and CDK4 are capable of inhibiting HER2 mediated tumorigenesis in genetically engineered mouse models, highlighting the importance of this cell cycle pathway in HER2 mediated oncogenesis (45-47). It has also recently been observed that amplification or overexpression of cyclin E is a mechanism of trastuzumab resistance (48). These published data on cyclin/CDK complexes support the concept that a gene, such as PPM1H, that is involved in regulation of p27 could play a role in HER2 signaling and trastuzumab resistance.

PPM1H expression was observed to be lower on average in the basal-like subtype of breast cancer which is well documented to be associated with poor prognosis. The basal-like expression pattern has also been reported to be associated with decreased p27 and increased SKP2 protein levels (39, 42). It should be noted that while on average basal-like cancers have lower PPM1H expression, there are basal-like cancers that have PPM1H expression similar to luminal tumors. In fact, the trend toward low PPM1H being associated with poor outcome was observed in the ER-negative (i.e. basal-like) population in the sample set of HER2-positive tumors. We also observed that on average PPM1H expression was lower in metastatic compared to primary tumors,
although clearly not all metastatic tumors had low PPM1H. Together the data in human
tumor tissues are consistent with the hypothesis that low PPM1H may be associated
with poor clinical outcome. However, further examination of PPM1H in larger clinical
data sets would be necessary to make more definitive conclusions. Further, the role of
PPM1H may differ depending on the cancer type.

The finding of PPM1H involvement in p27 mediated cell cycle regulation raises
potential therapeutic opportunities. PPM1H itself is not likely a therapeutic target since
inhibition causes elevated proliferation. However, it is possible that other proteins
downstream or upstream of PPM1H could represent therapeutic targets. In that regard,
small molecule CDK inhibitors have been reported to work in synergy with trastuzumab
(49). Further research to identify upstream factors that regulate PPM1H is thus of
potential importance. The identification of PPM1H opens new avenues of research into
a pathway that modulates p27 and raises potential new diagnostic and possibly
therapeutic strategies for patients who progress on HER2-targeted therapies such as
trastuzumab.
Materials and Methods

siRNA screen. Libraries targeting human kinase (795) and phosphatase (159) genes were obtained from Dharmacon. Each of 4 independent siRNAs were transferred to duplicate 96-well plates followed by addition of lipofectamine 2000 (Invitrogen) diluted with Optimem (Gibco). 20 min later, BT474 cells were plated (15000 cells per well) resulting in a final siRNA concentration of 25nM. Trastuzumab was added 24 h after transfection, and cell proliferation was determined 72 h later by measuring $^{3}$H-thymidine incorporation (3). Data for each well were normalized to the plate average. Genes for which at least 2 siRNAs were 1.5 standard deviations above the mean were considered hits.

Cell lines. BT474M1 is a subclone of BT474 that was adapted for growth in vivo and was obtained from California Pacific Medical Center. All other cell lines were originally obtained from American Type Culture Collection and cultured as previously described (3). Transient BT474 shRNA transfection was performed via electroporation (Nucleofactor, Lonza). Doxycycline-inducible PPM1H shRNA knockdown BT474M1 cells were produced via lentiviral transfection with a GFP-tagged PPM1H. 3D culture was performed as previously described (3). Phase contrast images were quantified using the Metamorph software package (Molecular Devices, a Danaher subsidiary; Washington, DC). Briefly, a bottom hat filter was used to correct for non-uniform illumination to allow for a binary threshold to identify cell-specific regions. Sequential opening and closing was then performed to consolidate cells and remove small non-cellular debris.

SNP genotypes are performed each time new cell line stocks are expanded for cryopreservation. Cell line identity is verified by high-throughput SNP genotyping.
using Illumina Golden gate multiplexed assays. SNPs were selected based on minor allele frequency and presence on commercial genotyping platforms (Supplementary Methods). SNP profiles were compared to SNP calls from available internal and external data to determine or confirm ancestry. In addition, Short Tandem Repeat (STR) Profiling was performed for each line using the Promega Cell ID™ System in which 10 human loci were assessed (nine STR loci and Amelogenin for gender identification), including D21S11, TH01, TPOX, vWA, Amelogenin, CSF1PO, D16S539, D7S820, D13S317 and D5S818. The STR profile is determined once and compared to external STR profiles of cell lines to determine cell line ancestry.

**Immunofluorescence.** Cells grown on coverslips were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. The cells were stained with p27 antibody (BD Biosciences) or SKP2 antibody (Invitrogen) followed by Alexa Flour 555-conjugated anti-mouse (Invitrogen) and then DAPI (Invitrogen). Images were acquired by the Ariol SL-50 automated slide scanning platform (Genetix Ltd.; Hampshire, UK) at 10x final magnification. Images were exported for analysis in the Metamorph software package (Molecular Devices, a Danaher subsidiary; Washington, DC) as individual images. Standard morphological filters were used to remove staining artifacts, and the cells were counted with the Cell Scoring application module.

**Preparation of recombinant PPM1H.** 293 cells were transfected with GST-PPM1H or GST-PPM1J plasmid using manufacturer’s protocol for Fugene6 (Roche). Pelleted cells were re-suspended in ice cold HKMT lysis buffer (20mM Hapes pH 7.2, 20mM KCl, 10mM MgCl2, 0.5% Triton X100, 10% glycerol with PTPase inhibitors (Roche)). Lysate was cleared by centrifugation and passed through a 1.5ml GSH-Sepharose column for 3 hours at 4°C. The column was washed with HKMT containing 0.4M NaCl for 10 column volumes, and eluted step-wise in 10mM GSH, 20 mM Hapes, 10mM
MgCl2, 0.5% Triton X100, 20mM MgCl2, 20% glycerol, and 5mM MnCl2 with 0.6ml elution fractions. Fractions containing full length GST-PPM1H were pooled and dialyzed overnight in ice-cold HKM containing 50% Glycerol. Aliquots were made and stored at -80°C. 35 plates (150 mm) of cells yielded 70-120 μg total protein with 70% full length enzyme. A similar protocol was used for production of recombinant flag-PPM1H except M2-anti-flag agarose (Sigma) was used as the resin and protein was eluted with sodium citrate at pH 3.0.

**Biochemical and ISH assays.** Antibodies used for Western blotting and immunoprecipitation were as follows: anti-Flag (Sigma); anti-HA (Roche Applied Sciences); anti-P27 (Santa Cruz Biotechnology or BD Biosciences); anti-phosphoP27 Thr 187 (Santa Cruz Biotechnology); anti-phosphoP27 Ser 10 (Santa Cruz Biotechnology); anti-PTEN (Santa Cruz Biotechnology); anti-PPM1H (peptide rabbit polyclonal); anti-SKP2 (Invitrogen); anti-α-tubulin (Sigma); anti-β-actin (MP Biomedicals).

PPM1H activity was assessed in a phosphate release from synthetic phosphopeptides using the Innova Biosciences Pi ColorLock Gold assay. Briefly 2 μg of peptide was treated with or without phosphatase in 0.1ml 20mM Hepes, 20 mM MgCl2, and 20mM KCl. Absorbance of molybdate complexed free phosphate was read at A635. λ-phosphatase was used as a positive control. In another approach, an HA-tagged p27 construct was transfected into HEK293 cells using Lipofectamine 2000 (Invitrogen). Cells were lysed in RIPA buffer (Sigma) supplemented with a Complete Mini, EDTA-free protease inhibitor tablet (Roche). 3 to 5 mg of cell lysate was incubated with anti-HA coupled agarose (Roche) overnight at 4°C then pelleted and washed three times in
RIPA buffer. The immunoprecipitated material was equilibrated with 2 washes in kinase buffer (5mM MOPS pH7.2, 0.4 mM EDTA, 5mM MgCl2) then phosphorylated with CDK2/CycA kinase (Cell Signaling Technologies, Beverly, MA) for 2 hours at 30°C. Samples were then washed three times in HKM buffer (40mM HEPES pH7.2, 20mM KCl, 20mM MgCl2) then treated with an equal amount of full-length GST-tagged recombinant phosphatase overnight at 30°C. Phosphatase treated material was then washed once with HKM buffer then eluted by heating at 95°C for 5 minutes in SDS sample buffer (Invitrogen). Samples were resolved by SDS PAGE and blotted onto nitrocellulose.

Isotopic in situ hybridization (ISH) was performed using a 591 bp probe starting at nucleotide 1597 of Genbank sequence NM_020700. The isotopically labelled slides were exposed to a phosphorimager which records the signal intensity per pixel. Separately, H&E stained slides were marked for high tumor content areas. The signal intensity per marked unit area of tumor was then determined for each sample. The population was ranked from lowest to highest PPM1H signal intensity and the patients whose tumors were in the lower 50th percentile for PPM1H expression were compared with those whose tumors were in the upper 50th percentile for PPM1H via Kaplan-Meier analysis. The survival curves were compared via the log-rank (Mantel-Cox) test using GraphPad Prism software. A similar analysis was performed in ER-negative and ER-positive patients separately.
Acknowledgments

The authors would like to thank the Genentech Pathology Core Laboratories and Department of Protein Engineering for technical support and Cherry Lei for statistics support. Gary Pestano at Ventana Medical Systems, Inc is acknowledged for performing the PTEN IHC staining run. The authors also acknowledge the Gene Logic Corporation, Gaithersburg MD for preparing the raw Affymetrix expression data.
References


<table>
<thead>
<tr>
<th>Genes</th>
<th># siRNA above threshold</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Z-score &gt; 1.5</td>
<td>Z-score &gt; 2</td>
<td></td>
</tr>
<tr>
<td>CDKN1B</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>PTEN</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>OBSCN</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>PPM1H</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>PTPN11</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>DAK</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>DUSP6</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>HK2</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>ITK</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>PDLIM5</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>MAPK8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>RYK</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>CDC42SE2</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>STK22C</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>CDK11B</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>TPRXL</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>ITPK1</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>LATS2</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>MAP4K4</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>PANK1</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>WNK3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>SOCS5</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>TXNDC3</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>WEE1</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>PPP6R2</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>DGK1</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>DUSP4</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>DYRK1A</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>FLT1</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>STYK1</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>STK10</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>
Figure Legends

Figure 1. siRNA screen validation. (A) Schematic representation of the screen format. (B) Screening conditions were optimized using PTEN and p27 siRNA as positive controls. Both PTEN and p27 siRNA cause increased proliferation in the presence of trastuzumab. (C) Z-scores of individual siRNA oligonucleotides from human kinases (left graph) and phosphatases (right graph). Z-scores above 1.5 (red line, 1.5 standard deviations above the plate mean) were considered hits. p27 (blue triangles) and PTEN (yellow squares) were both in the library and all 4 oligonucleotides targeting each gene are marked on the graph.

Figure 2. Trastuzumab resistance siRNA screen identifies PPM1H. (A) Knockdown of PTEN, p27, 3 novel kinases and 2 novel phosphatases in BT474M1 cells with and without trastuzumab (mean ± SEM). % knockdown by qRT-PCR is noted for each gene. (B) PPM1H or control shRNA was transfected with a GFP vector or a GFP-PPM1H-SM vector harbouring silent mutations in the shRNA binding region. GFP-positive cells were quantified (mean ± SEM). (C) PPM1H knockdown with and without trastuzumab treatment was tested in 3D culture using a doxycycline inducible BT474M1-PPM1H shRNA cell line. Data with a negative control shLacZ cell line are shown in Supplementary Fig. 3A. Colony area is represented by box and whisker plot (whiskers represent 5th and 95th percentile).

Figure 3. PPM1H regulates expression of p27 and SKP2. (A) Western blot showing expression of p27, SKP2, PPM1H, and PTEN with and without siRNA knockdown of the same genes. (B) p27 immunofluorescence with and without PPM1H knockdown and with and without trastuzumab treatment. (C) SKP2 immunofluorescence with and without PPM1H knockdown and with and without trastuzumab treatment. Scale bar = 100 μm.
**Figure 4. PPM1H is a p27-T187 phosphatase.** (A) Recombinant flag-PPM1H activity was tested on p27 and SKP2 phospho-peptides in a phosphate release assay. λ-phosphatase was used as a positive control. Activity was observed only on p27, particularly at the T187 site. (B and C) Recombinant PPM1H activity was examined on HA-p27 pre-treated with CDK2/cyclin A to phosphorylate the T187 site of p27. One-tenth of the kinase reaction was examined to ensure equal p27 phosphorylation (Pre-Phosphatase Tx). (B) Recombinant flag-PPM1H and flag-PPM1H-H153L were tested in a phosphatase reaction. (C) Recombinant GST-PPM1H and GST-PPM1J were tested in a phosphatase reaction.

**Figure 5. Low PPM1H expression is associated with poor clinical outcome.** (A) PPM1H was assessed by isotopic in situ hybridization in tumour tissue from 87 metastatic breast cancer patients who had been treated with trastuzumab until progression, toxicity, death, or patient choice (33). The PPM1H signal was quantified via phosphorimager in areas of high tumor content. Using the median expression as a cutoff, Kaplan-Meier analysis reveals a hazard ratio of 1.60 for low PPM1H (p = 0.07, 95%CI 0.96-2.65). (B) PPM1H expression was examined in breast cancer cell lines subgrouped into basal and luminal (34) by HER2 status. (C) PPM1H expression was examined in 261 breast tumours subgrouped into basal and luminal (34) by HER2 status.

**Figure 6. Model of PPM1H regulation of p27.** The evidence suggests that PPM1H is a phosphatase for the T187 site on p27. By dephosphorylating p27, PPM1H would promote p27 stability. As such, loss of PPM1H would be expected to destabilize p27 and promote proliferation.
**A**

1. BT474 cells-96 well plate
2. Reverse transfection
3. Control RNAi
4. RNAi library
5. + Trastuzumab
6. $^{3}$H-Thymidine assay
7. Analysis

**B**

- 3H-Thymidine uptake
- Untreated
- Trastuzumab
- NTC
- PTEN
- P27

**C**

- Cell Proliferation (Z-scores)
- Kinase Library
- Phosphatase Library

Downloaded from cancerdiscovery
Figure A: Bar graph showing 3H-thymidine uptake with % Knockdown vs. NTC: NTC 93, p27 94, PTEN 77, DYRK1A 82, STK10 82, STYK1 91, PPM1H 92, PTPN11.

Figure B: Graph showing GFP+ cell count normalized to Untreated. Untreated and Trastuzumab conditions are compared.

Figure C: Box plot showing Acinus area under different conditions: Unt, Dox, Tmab, Dox+Tmab.
PPM1H is a p27 phosphatase implicated in trastuzumab resistance

Si Tuen Lee-Hoeflich, Thinh Q. Pham, Don Dowbenko, et al.

Cancer Discovery Published OnlineFirst July 20, 2011.